Microchip Technology Inc. vs Pfizer Inc — how do they compare? Microchip Technology Inc. trades at $81.69 (market cap $44.20B), while Pfizer Inc trades at $26.6 (market cap $154.18B). The key difference: Pfizer Inc is far larger — about 3.5× Microchip Technology Inc.'s market cap, and Pfizer Inc pays the higher dividend (6.36%). Which is the better fit depends on your goals.
| MCHP | PFE | |
|---|---|---|
Market Cap | $44.20B | $154.18B |
Sector | Technology | Health |
52-Week High | $102.97 | $28.56 |
52-Week Low | $49.02 | $23.60 |
Enterprise Value | $49.32B | $205.67B |
Dividend Yield | 2.24% | 6.36% |
Volume | — | 29,869,932 |
Signals from Pluang's Aura AI — not financial advice
Microchip Technology (MCHP) trades at $84.69, up 13.89% in 24 hours, reflecting strong momentum. The stock is in a bullish technical trend, with recent earnings beats and robust data center revenue growth of 98% last quarter. Analyst consensus is strongly bullish with a $104 price target. However, valuation ratios like a P/E of 124.54 are elevated, and 2025 net income was negative, posing fundamental concerns despite a recovery forecast for 2026.
Outlook is positive driven by AI and data center demand, but high valuation and past profitability volatility are risks. The stock offers growth exposure amid analyst optimism, yet investors should weigh premium pricing against execution risks in a competitive semiconductor market.
Pfizer (PFE) trades at $26.62, down 0.45% today, with a bullish technical signal from moving averages and a consensus analyst price target of $27.86. The company reported three consecutive quarterly earnings beats in 2026, with Q3 2026 EPS expected at $0.79. Revenue for 2025 was $62.58 billion, with a net income margin of 12.41%, though 2026 projections show a decline to 6.8%. Positive news highlights pipeline advancements in obesity and oncology therapies.
Pfizer presents a mixed outlook: bullish technicals and analyst support contrast with declining profit margins and patent cliff risks. Investment opportunities include a solid dividend yield and catalyst-rich pipeline in 2026, but risks involve revenue volatility post-COVID and competitive pressures. The stock's current valuation at a P/E of 35.59 may limit near-term upside absent earnings acceleration.
Trailing returns across standard periods
Latest headlines on both assets
Microchip became an independent company in 1989 when it was spun off from General Instrument. More than half of revenue comes from MCUs, which are used in a wide array of electronic devices from remote controls to garage door openers to power windows in autos. The company's strength lies in lower-end 8-bit MCUs that are suitable for a wider range of less technologically advanced devices, but the firm has expanded its presence in higher-end MCUs and analog chips as well.
Read more on MCHP →Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →